Ticker LaunchReverse merger · Completed · ELTX
Elicio Therapeutics, Inc.
Reverse merger with Angion Biomedica Corp. (ANGN)
Elicio Therapeutics, Inc. merged into Angion Biomedica Corp. (ANGN), a biopharma developing small-molecule therapeutics for fibrotic diseases, in a reverse merger that takes the private company public. The deal was announced on Jan 17, 2023 and closed on Jun 2, 2023. The combined company trades as Elicio Therapeutics, Inc. (ELTX) on Nasdaq.
Elicio Therapeutics is a clinical-stage immunotherapy company using its lymph node-targeting Amphiphile (AMP) technology, led by the ELI-002 program. It became Nasdaq-listed via merger with Angion.
- Status
- Completed
- Private company
- Elicio Therapeutics, Inc.
- Public company
- Angion Biomedica Corp. (ANGN)
- Public company business before
- biopharma developing small-molecule therapeutics for fibrotic diseases
- Announced
- Jan 17, 2023
- Closed
- Jun 2, 2023
- Combined company
- Elicio Therapeutics, Inc. (ELTX)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Announcement press release
- Closing 8-K Jun 2, 2023
- Closing press release
- All filings on EDGAR CIK 1601485
Other completed reverse mergers
- Proton Green, LLCinto Cyber App Solutions Corp. · Jul 17, 2023
- Glamourous Groupinto Luduson G Inc. · Jul 6, 2023
- Cibus Global, LLCinto Calyxt, Inc. · May 31, 2023
- U.S. Minerals and Metals Corp. (USMM)into INKY Inc. · May 16, 2023
- Prairie Operating Co., LLCinto Creek Road Miners, Inc. · May 3, 2023
- GRI Bio Operations, Inc.into Vallon Pharmaceuticals, Inc. · Apr 21, 2023